Immunotherapy of cancer: recent progress and future challenges
Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden
Immunotherapy of cancer: recent progress and future challenges ( Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden )
6 Jan 2015
Reasons to attend the EurocanPlatform translational research course 2015
Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany
Reasons to attend the EurocanPlatform translational research course 2015 ( Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany )
6 Jan 2015
2nd EurocanPlatform translational research course is good for networking
Dr Diana Montezuma, Portuguese Oncology Institute of Porto, Portugal
2nd EurocanPlatform translational research course is good for networking ( Dr Diana Montezuma, Portuguese Oncology Institute of Porto, Portugal )
6 Jan 2015
Biobanking biological materials and linkage to clinical information
Dr Peter Riegman, Erasmus Medical Center, Rotterdam, The Netherlands
Biobanking biological materials and linkage to clinical information ( Dr Peter Riegman, Erasmus Medical Center, Rotterdam, The Netherlands )
6 Jan 2015
The role of health economics in cancer outcomes research
Prof Bengt Jönsson, Stockholm School of Economics, Stockholm, Sweden
The role of health economics in cancer outcomes research ( Prof Bengt Jönsson, Stockholm School of Economics, Stockholm, Sweden )
6 Jan 2015
Summary of breaking prostate news from ASCO 2014
Prof Eleni Efstathiou and Prof Gordon McVie
Summary of breaking prostate news from ASCO 2014 ( Prof Eleni Efstathiou and Prof Gordon McVie )
2 Jun 2014
Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014
Prof Franco Cavalli, Prof Gordon McVie
Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014 ( Prof Franco Cavalli, Prof Gordon McVie )
1 Jun 2014
Idelalisib shows promising results in patients with double refractory indolent B...
Dr Andrew Davies - Southampton General Hospital, Southampton, UK;
Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma ( Dr Andrew Davies - Southampton General  Hospital, Southampton, UK; )
9 May 2014
New agents extend progression-free survival in double refractory myeloma
Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, US...
New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute  of Emory University, Atlanta, USA )
8 May 2014
Role of AORTIC in dealing with rising cancer rates in Africa
North American Vice president of AORTIC
Role of AORTIC in dealing with rising cancer rates in Africa ( North American Vice president of AORTIC )
1 May 2014
ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bo...
Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden
ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases ( Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden )
1 Feb 2014